论文部分内容阅读
目的:评价甲氨蝶呤、柳氮磺吡啶与硫酸羟氯喹联用对类风湿性关节炎(RA)患者相关生化指标的影响。方法:选取2013年7月—2015年2月间风湿免疫科收治的RA患者90例作为研究对象,按照抽签法将其分为对照组(n=45)和治疗组(n=45);治疗组患者给予甲氨蝶呤、柳氮磺吡啶与硫酸羟氯喹联用治疗,对照组患者给予甲氨蝶呤与血脂康联用治疗,比较两组患者治疗前及治疗后180 d各血脂及其RA相关指标的改善情况。结果:治疗前后,两组患者各血脂指标水平经比较其差异无统计学意义(P>0.05);与治疗前相比,治疗组患者关节肿胀数、关节压痛数以及CRP、DAS28、ESR水平值低于对照组(P<0.05);治疗后治疗组患者RA相关指标经比较其差异有统计学意义(P<0.05);治疗180 d后,两组患者LDL-C、TC、TG等水平均低于治疗前,HDL-C水平明显高于治疗前(P<0.05)。结论:类风湿性关节炎患者存在血脂异常现象,采用甲氨蝶呤、柳氮磺吡啶与硫酸羟氯喹联合治疗的疗效较为显著,优于甲氨蝶呤与血脂康联用的疗效。
Objective: To evaluate the effects of combination of methotrexate, sulfasalazine and hydroxychloroquine on the biochemical parameters in patients with rheumatoid arthritis (RA). Methods: Totally 90 RA patients admitted to the department of rheumatology from July 2013 to February 2015 were selected as the control group (n = 45) and the treatment group (n = 45) Group methotrexate, sulfasalazine and hydroxychloroquine sulfate combination therapy, patients in the control group were given methotrexate and Xuezhikang combined treatment, two groups of patients before treatment and 180 d after treatment of each lipid and its RA-related indicators of the improvement. Results: Before and after treatment, there was no significant difference in the level of blood lipid between the two groups (P> 0.05). Compared with before treatment, the number of joint swelling, joint tenderness, CRP, DAS28 and ESR (P <0.05). After treatment, the relative indexes of RA in the treatment group were statistically significant (P <0.05). After 180 days of treatment, the levels of LDL-C, TC and TG in both groups were significantly lower than those in the control group Lower than before treatment, HDL-C levels were significantly higher than before treatment (P <0.05). Conclusion: Dyslipidemia exists in patients with rheumatoid arthritis. The combination of methotrexate, sulfasalazine and hydroxychloroquine sulfate is more effective than the combination of methotrexate and Xuezhikang.